IceCure Medical Ltd (NASDAQ:ICCM) Short Interest Update

IceCure Medical Ltd (NASDAQ:ICCM) was the target of a significant growth in short interest during the month of November. As of November 15th, there was short interest totalling 2,310,000 shares, a growth of 718.6% from the October 31st total of 282,200 shares. Based on an average daily volume of 677,400 shares, the days-to-cover ratio is presently 3.4 days. Currently, 10.5% of the shares of the company are short sold.

IceCure Medical Stock Performance

Shares of ICCM stock opened at $0.83 on Thursday. The company has a current ratio of 2.97, a quick ratio of 2.54 and a debt-to-equity ratio of 0.03. The stock has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.73. The company has a market cap of $37.96 million, a price-to-earnings ratio of -2.77 and a beta of 0.48. IceCure Medical has a 12-month low of $0.48 and a 12-month high of $1.57.

Analysts Set New Price Targets

ICCM has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and set a $2.50 price target on shares of IceCure Medical in a report on Wednesday. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a research note on Friday, November 1st.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in IceCure Medical stock. Renaissance Technologies LLC bought a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned approximately 0.15% of IceCure Medical as of its most recent filing with the SEC. 0.62% of the stock is owned by institutional investors and hedge funds.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.